Published Date: 10 Mar 2023
A recent study by Ruifang Zhang and colleagues showed that aminophylline reduced the risk of death and prolonged survival in patients with sepsis. more...
Read Full NewsComplicated eligibility rules, stigma surrounding smoking and lung cancer, and confusion about the screening process continue to keep many high-risk patients from getting screened.
A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.
The FDA says the increased risk of hematologic secondary primary malignancies with tazemetostat now outweighs the benefits of the drug; Ipsen pulls it from the market.
The BCL-2 inhibitor was granted accelerated approval based on findings from the phase 1/2 BGB-11417-201 study.
1.
One-third of childhood cancer survivors experience significant fear that it could come back, study reveals
2.
A Win for AI in Cancer; 2025's Transformative Drugs; FDA Clarifies 'Underway' Trials
3.
Gene therapy and chemotherapy may be combined in novel ways to treat bone cancer.
4.
Pooled Cord Blood Transplants Achieve Near-Perfect Results in Early Trial
5.
June 20, 2023, Health Bulletin No. 12.
1.
What Is Carboxyhemoglobin And How Can It Affect Your Health?
2.
Unpacking the Importance of White Blood Cells (WBCs) in the Body
3.
Synovial Sarcoma of Female Urethra: Case Report and Literature Review
4.
Pharmacological Frontier of Precision Oncology, Immunotherapies, and the Evolving Art of Treatment
5.
Protein S-Palmitoylation in Cancer: A Novel Target in Immunotherapy & Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
2.
Efficient Management of First line ALK-rearranged NSCLC
3.
Efficient Management of First line ALK-rearranged NSCLC - Part II
4.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
5.
Navigating the Complexities of Ph Negative ALL - Part XII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation